149 related articles for article (PubMed ID: 15219555)
1. Global strategies to prevent bacterial pneumonia in adults with HIV disease.
Feikin DR; Feldman C; Schuchat A; Janoff EN
Lancet Infect Dis; 2004 Jul; 4(7):445-55. PubMed ID: 15219555
[TBL] [Abstract][Full Text] [Related]
2. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
[TBL] [Abstract][Full Text] [Related]
3. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world.
Kaplan JE; Hu DJ; Holmes KK; Jaffe HW; Masur H; De Cock KM
Am J Trop Med Hyg; 1996 Jul; 55(1):1-11. PubMed ID: 8702012
[TBL] [Abstract][Full Text] [Related]
4. Community-acquired pneumonia in HIV-infected children: a global perspective.
Gray DM; Zar HJ
Curr Opin Pulm Med; 2010 May; 16(3):208-16. PubMed ID: 20375782
[TBL] [Abstract][Full Text] [Related]
5. [Incidence of bacterial pneumonia in HIV-positive patients treated with preventive co-trimoxazole or pentamidine].
Koch A; Kothe H; Braun J; Kämmerer R; Friedrich HJ; Dalhoff K
Pneumologie; 1998 Nov; 52(11):614-21. PubMed ID: 9885511
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
8. Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries.
Zachariah R; Harries AD; Luo C; Bachman G; Graham SM
Lancet Infect Dis; 2007 Oct; 7(10):686-93. PubMed ID: 17897611
[TBL] [Abstract][Full Text] [Related]
9. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group.
Hirschtick RE; Glassroth J; Jordan MC; Wilcosky TC; Wallace JM; Kvale PA; Markowitz N; Rosen MJ; Mangura BT; Hopewell PC
N Engl J Med; 1995 Sep; 333(13):845-51. PubMed ID: 7651475
[TBL] [Abstract][Full Text] [Related]
10. Co-trimoxazole prophylaxis in African children with HIV-1.
Madhi SA; Zar HJ; Saloojee H; Gray GE
Lancet; 2005 Feb 26-Mar 4; 365(9461):749-50; author reply 750-1. PubMed ID: 15733707
[No Abstract] [Full Text] [Related]
11. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
Chaisson RE; Keruly J; Richman DD; Moore RD
Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
[TBL] [Abstract][Full Text] [Related]
12. Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
Le Moal G; Breux JP; Roblot F
N Engl J Med; 2001 May; 344(21):1639-41. PubMed ID: 11374363
[No Abstract] [Full Text] [Related]
13. [Withdrawal of Pneumocystis carinii pneumonia prophylaxis in patients receiving efficacious combined antiretroviral treatment. Study of 85 cases].
García Vázquez E; de Górgolas Hernández M; García Delgado R; Fernández Guerrero ML
Med Clin (Barc); 1999 Jun; 113(3):89-90. PubMed ID: 10464742
[TBL] [Abstract][Full Text] [Related]
14. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
[TBL] [Abstract][Full Text] [Related]
15. Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
Bender MA; Sax PE
N Engl J Med; 2001 May; 344(21):1639; author reply 1640-1. PubMed ID: 11374364
[No Abstract] [Full Text] [Related]
16. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases.
Dworkin MS; Williamson J; Jones JL; Kaplan JE;
Clin Infect Dis; 2001 Aug; 33(3):393-8. PubMed ID: 11438910
[TBL] [Abstract][Full Text] [Related]
17. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy.
Jordano Q; Falcó V; Almirante B; Planes AM; del Valle O; Ribera E; Len O; Pigrau C; Pahissa A
Clin Infect Dis; 2004 Jun; 38(11):1623-8. PubMed ID: 15156452
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.
Peñaranda M; Falco V; Payeras A; Jordano Q; Curran A; Pareja A; Samperiz G; Dalmau D; Ribera E; Riera M
Clin Infect Dis; 2007 Oct; 45(7):e82-7. PubMed ID: 17806042
[TBL] [Abstract][Full Text] [Related]
19. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
